

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (original) A molecule which contains a partially occluded and/or multimeric presentation of a peptide which is recognised by an HIV-1 neutralising antibody capable of neutralising diverse clinical isolates of HIV-1.
2. (original) A molecule as claimed in claim 1 wherein the HIV-1 neutralising antibody is any of 2F5, IgG<sub>1</sub>-b12, 4E10 and Z13.
3. (currently amended) A molecule as claimed in claim 1 ~~or claim 2~~ wherein the peptide contained within the molecule is a linear epitope of the HIV-1 neutralising antibody.
4. (currently amended) A molecule as claimed in claim 1 ~~any of claims 1 to 3~~ which is a homomultimer of a polypeptide chain which polypeptide chain contains a spacer portion, a linear epitope recognised by the HIV-1 neutralising antibody, a multimerisation portion and, optionally, a carrier portion wherein the polypeptide chain has a molecular weight no more than 30 kDa.
5. (currently amended) A molecule as claimed in claim 1 ~~any of claims 1 to 3~~ comprising a portion which is a linear epitope recognised by the HIV-1 neutralising antibody and an occluding portion.
6. (currently amended) A molecule as claimed in claim 1 which is a polypeptide of one or more polypeptide chains.
7. (currently amended) A molecule as claimed in claim 1 ~~any of the preceding claims~~ which is a homomultimer of a polypeptide chain which contains a linear epitope which recognises the HIV-1 neutralising antibody and an occluding

portion wherein the linear epitope is partially occluded by the occluding portion when the polypeptide chain is present in the multimer.

8. (currently amended) A molecule as claimed in claim 1 ~~any of claims 1 to 7~~ comprising a first polypeptide chain which contains a linear epitope of the HIV-1 neutralising antibody and a second polypeptide chain which partially occludes the linear epitope on the first polypeptide chain.

9. (original) A molecule as claimed in claim 7 wherein the polypeptide chain contains an occluding portion, the linear epitope, a multimerisation portion and, optionally, a carrier portion.

10. (original) A molecule as claimed in claim 8 wherein the first polypeptide chain contains (1) the linear epitope, (2) a multimerisation portion and, optionally, (3) a carrier portion, and the second polypeptide chain comprises an occluding portion, a multimerisation portion and, optionally, a carrier portion.

11. (original) A trimeric presentation of a peptide as defined in claim 1.

12. (currently amended) A multimeric presentation of a peptide as defined in claim 1 ~~or claim 2~~ which is stabilised by inter-chain disulphide bridging of the reactive peptides or by other chemical means to generate a three dimensional structure similar to that created by the disulphide-bridged peptides.

13. (currently amended) A polynucleotide encoding a polypeptide chain as claimed in claim 6 ~~any of claims 6 to 12~~.

14. (canceled)

15. (currently amended) A pharmaceutical composition comprising a molecule as claimed in claim 1 ~~any of claims 1 to 10~~, or a trimeric or multimeric presentation of a peptide as defined in claim 1 as claimed in claims 11 or 12, or a polynucleotide encoding a peptide as defined in claim 1 as claimed in claim 13 and a pharmaceutically acceptable carrier.

16. (canceled)

17. (currently amended) A method of obtaining an HIV-1 neutralising antibody, the method comprising administering a molecule as claimed in claim 1 ~~any of claims 1 to 10~~, or a trimeric or multimeric presentation of a peptide as defined in claim 1 ~~as claimed in claims 11 or 12~~, or a polynucleotide encoding a peptide as defined in claim 1 ~~as claimed in claim 13~~ to an animal, allowing the animal to produce antibodies, and recovering antibodies directly or indirectly from the animal.

18. (original) A method as claimed in claim 17 wherein the antibodies are monoclonal antibodies.

19. (currently amended) A method of obtaining an HIV-1 neutralising antibody, the method comprising selecting an antibody from an antibody display library *in vitro* which binds to a molecule as claimed in claim 1 ~~any of claims 1 to 10~~, or a trimeric or multimeric presentation of a peptide as defined in claim 1 ~~as claimed in claims 11 or 12~~, and synthesising an antibody containing the binding determinants of the so selected antibody.

20. (currently amended) An antibody obtained in accordance with claim 17 ~~or 19 any of claims 16 to 19~~ capable of neutralising diverse clinical isolates of HIV-1.

21. (canceled)

22. (original) A pharmaceutical composition comprising an antibody as claimed in Claim 20 and a pharmaceutically acceptable carrier.

23. (currently amended) A vaccine for the prevention or treatment of HIV-1 infection which comprises a molecule as claimed in claim 1 ~~any of claims 1 to 10~~, or a trimeric or multimeric presentation of a peptide as defined in claim 1 ~~as claimed in claims 11 or 12~~, or a polynucleotide encoding a peptide as defined in claim 1 ~~as claimed in claim 13~~.

24. (canceled)

25. (currently amended) A method of treating or preventing HIV-1 infection in an individual the method comprising administering to the individual a molecule as claimed in claim 1 ~~any of claims 1 to 10~~, or a trimeric or multimeric presentation of a peptide as defined in claim 1 ~~as claimed in claims 11 or 12~~, or a polynucleotide encoding a peptide as defined in claim 1 ~~as claimed in claim 13~~, or an antibody ~~as claimed in claim 20~~.

26. (currently amended) A method of detecting HIV-1 neutralising antibodies in a sample the method comprising contacting the sample with a molecule as claimed in claim 1 ~~any of claims 1 to 10~~ or a trimeric or multimeric presentation of a peptide as defined in claim 1 ~~as claimed in claims 11 or 12~~ and determining whether any antibodies present in the sample bind thereto.

27. (original) A method of identifying a molecule which may be useful in raising a neutralising response to HIV-1 the method comprising screening a peptide display library wherein the displayed peptides are from 15 to 40 amino acids in length with an HIV-1 neutralising antibody and selecting those displayed peptides which bind to the antibody.

28. (original) A method according to claim 27 further comprising determining whether the displayed peptides are able to bind to an antibody raised against a linear epitope recognised by the HIV-1 neutralising antibody and selecting those displayed peptides that are not able to so bind.

29. (currently amended) A molecule obtained by the method of claim 27 ~~or~~ 28.

30. (new) A method of treating or preventing HIV-1 infection in an individual the method comprising administering to the individual an antibody as claimed in claim 20.